Last reviewed · How we verify

Paroxetine CR for Major Depressive Episode

New York State Psychiatric Institute · FDA-approved active Small molecule Quality 2/100

Paroxetine CR for Major Depressive Episode is a Small molecule drug developed by New York State Psychiatric Institute. It is currently FDA-approved. Also known as: Paxil CR.

At a glance

Generic nameParoxetine CR for Major Depressive Episode
Also known asPaxil CR
SponsorNew York State Psychiatric Institute
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Paroxetine CR for Major Depressive Episode

What is Paroxetine CR for Major Depressive Episode?

Paroxetine CR for Major Depressive Episode is a Small molecule drug developed by New York State Psychiatric Institute.

Who makes Paroxetine CR for Major Depressive Episode?

Paroxetine CR for Major Depressive Episode is developed and marketed by New York State Psychiatric Institute (see full New York State Psychiatric Institute pipeline at /company/new-york-state-psychiatric-institute).

Is Paroxetine CR for Major Depressive Episode also known as anything else?

Paroxetine CR for Major Depressive Episode is also known as Paxil CR.

What development phase is Paroxetine CR for Major Depressive Episode in?

Paroxetine CR for Major Depressive Episode is FDA-approved (marketed).

Related